BioSpace News Archive

Rhythm Pharmaceuticals, Inc. today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) have granted pre-marketing authorization AP1 (autorisation d’accès précoce - early access authorization),

InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer, will present at the Canaccord 42nd Annual Growth Conference on Aug. 11, 2022, at the InterContinental Boston hotel.

Univar Solutions Inc. (NYSE: UNVR) (“Univar Solutions”), announced today that NexusBioAg, have reached an exclusive marketing and distribution agreement in the Canadian canola and pulse market for TerraMG™, a mustard-derived soil biopesticide technology.

Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of the global Phase 3.

Nanostics Inc., a precision health diagnostics company, is excited to launch a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX® diagnostic platform.

Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).

TELA Bio, Inc. today announced that it has been awarded a group purchasing agreement for Synthetic Bioabsorbable Mesh Products with Premier, Inc.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that it has been selected to provide CDMO services to support the ongoing clinical development of a novel drug candidate in Europe.

Femasys Inc. today announced that, in the wake of the overturn of Roe v. Wade , it will host a key opinion leader (KOL) event to discuss FemBloc, the Company’s proprietary, first-of-its kind medical solution for permanent birth control, on Thursday, July 28th.

Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report second quarter fiscal 2022 financial results on Wednesday, August 10, 2022 , before the market opens.